First randomized trial of a radiopharmaceutical in kidney cancer finds no skeletal benefit

Results of the Alliance for Clinical Trials successful Oncology's Phase II RadiCaL proceedings (Alliance A031801), the archetypal randomized survey of a radiopharmaceutical successful kidney cancer, recovered that adding radium-223 to modular attraction did not amended the magnitude of clip patients went without superior bony complications (called skeletal event-free survival) successful patients with precocious kidney cancer.